Researchers at the University of California San Diego School of Medicine have validated a more comprehensive genetic tool for predicting age of onset of aggressive prostate cancer. Brotherhood of the Balloon, a COMPPARE Partner Organization, told their BOB Tales summer newsletter…
Dear COMPPARE team, participants, stakeholders and friends, I am pleased to report that as of August 20 we have enrolled 1,783 prostate cancer patients in COMPPARE, while striving to reach our accrual goal of 900 Pragmatic Proton patients by the end of August. We are working hard to achieve these…
A Message from Dr. Nancy Mendenhall COMPPARE has achieved both a remarkable overall accrual rate and a remarkable accrual rate of minorities. In fact, the study stands to become a model for patient-centric clinical research in the future. Read Dr. Mendenhall’s message. Partner Site…
A Message from Dr. Nancy Mendenhall As we look forward to the normal resumption of our work, we ask you to join us in an effort to encourage all men to get back to having their prostates checked annually in order to detect cancers…
A Message from Dr. Nancy Mendenhall I am thrilled to announce that we have reached 40% of our accrual goal! Our progress is truly astonishing, given the continued challenges COVID-19 has presented us with both globally and locally. Read Dr. Mendenhall’s message.
A Message from Dr. Nancy Mendenhall Despite the challenges that we and other cancer research studies continue to face in this unprecedented time of COVID-19, COMPPARE has made significant progress toward our ultimate goal of helping prostate cancer patients make informed treatment decisions. Read…
Thank you for your interest in the COMPPARE study. Patient enrollment is now closed. COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” This study, which is funded by the Patient-Centered Outcomes Research Institute (PCORI) and approved by the University…
Thank you for your interest in the COMPPARE study. Patient enrollment is now closed. COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” This study is funded by the Patient-Centered Outcomes Research Institute (PCORI) and led by…
Participation Flow Chart Steps taken by patients who are eligible for COMPPARE. View the participation flow chart.
